New Version Available!
Users are strongly advised to only use the latest, up-to-date versions of DIANA-Tools and Databases.
Please follow this link to navigate to the latest database version.
Please follow this link to navigate to the latest database version.
Please cite:
I. S. Vlachos, M. D. Paraskevopoulou, D. Karagkouni, G. Georgakilas, T. Vergoulis, I. Kanellos, I-L. Anastasopoulos, S. Maniou, K. Karathanou, D. Kalfakakou, A. Fevgas, T. Dalamagas and A. G. Hatzigeorgiou. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucl. Acids Res. (2014)
Data Download:
|
||||||||
Related Pathways
Publication year
Prediction score
Filters
Selected:
Species: -
Regulation: -
Validation: -
Validated: -
Sources: -
Methods: -
Species: -
Regulation: -
Validation: -
Validated: -
Sources: -
Methods: -
Remove all 
Species
Method Type
Method
Regulation type
Validation type
Validated as
Source
Publication year
Prediction score
Gene name
miRNA name
Methods
Pred.Score
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604572 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604572 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604670 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604572 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604670 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604670 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163608809-163608827 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604572 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604670 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604670 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163610476-163610500 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604670 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604670 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604670 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604670 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163608809-163608827 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163610476-163610498 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604572 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604572 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604670 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604670 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604572 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604670 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604670 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163608809-163608835 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604572 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163610476-163610500 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604670 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604670 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604670 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163608809-163608827 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163610476-163610498 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604669 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604669 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604669 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604669 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163608809-163608835 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163610476-163610500 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604676 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604676 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604676 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604676 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163608809-163608828 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163610476-163610500 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604667 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604648-163604667 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604667 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604648-163604667 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163608809-163608833 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604546-163604569 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163610476-163610498 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604516-163604541 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604516-163604538 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604516-163604540 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604547-163604568 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604547-163604568 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604649-163604665 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604649-163604665 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604547-163604568 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604649-163604665 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163604649-163604665 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604547-163604568 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163610477-163610498 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163603899-163603920 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163603899-163603920 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163606172-163606195 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163603899-163603920 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163603899-163603920 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604662-163604677 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604656-163604678 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163608879-163608902 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163603580-163603607 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163608813-163608827 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163606421-163606449 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163608813-163608827 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163606421-163606444 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163606421-163606441 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163606421-163606440 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163603335-163603360 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163608886-163608914 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163606252-163606273 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163609006-163609025 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163609009-163609030 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163606172-163606193 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163611282-163611302 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163611282-163611308 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163603677-163603692 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163610610-163610631 (UNKNOWN)
Primary human umbilical vein endothelium. AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163603677-163603692 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604036-163604052 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163605151-163605172 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604036-163604058 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604036-163604060 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604036-163604056 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604036-163604059 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163611100-163611120 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604608-163604631 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163610990-163611005 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163611098-163611122 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-21-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
Microarray
Other
UNKNOWN
UNKNOWN
miRTarBase
FIGN (hsa)
hsa-miR-34a-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
Sequencing
Other
UNKNOWN
UNKNOWN
miRTarBase
FIGN (hsa)
hsa-miR-342-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
CLASH
Other
UNKNOWN
UNKNOWN
miRTarBase
FIGN (hsa)
hsa-miR-21-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
Microarrays
POSITIVE
INDIRECT
TarBase 6.0
FIGN (hsa)
kshv-miR-K12-5*
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604650-163604673 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-766-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163610989-163611012 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-17-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163603399-163603426 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-30a-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163607540-163607559 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-93-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163603399-163603427 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163606424-163606449 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-181a-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163608887-163608906 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163607759-163607782 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163608772-163608792 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163608838-163608854 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-181b-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163609585-163609612 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163608887-163608911 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-181c-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163608887-163608905 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163607759-163607781 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr2:163608772-163608799 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-219-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163605147-163605166 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-30e-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163607540-163607559 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-151a-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604551-163604574 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-196a-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163604611-163604633 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-522-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:164461311-164461357 (UNKNOWN)
We applied an unbiased sequencing-based systems approach to characterize miR-522, a member of the oncogenic primate-specific chromosome 19 miRN cluster, highly expressed in poorly differentiated cancers. To identify miRN targets, we sequenced full-length transcripts captured by a biotinylated miRN mimic. Within these targets, mostly noncanonical MREs were identified by sequencing RNase-resistant fragments.
IMPACT-Seq
POSITIVE
DIRECT
Tarbase 7.0
FIGN (hsa)
hsa-miR-181d
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:163609585-163609612 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:163608887-163608910 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0